Superluminal Medicines
Overview
Where Superluminal Medicines is now
Superluminal Medicines announced a Series B round of $60M on 3 September 2026, led by BVF Partners.
Observed Described in the funding announcement as "biotechnology company integrating AI/ML, protein dynamics, and structural biology to generate G protein-coupled receptor (GPCR) targets". Source
Current direction Inferred
What this company is working on
Read from the company's own description of what the funding supports.
What happens next
What this raise plausibly creates
Likely next Moves
- New market entry
- First local hires in the new market
- Local entity and legal setup
- Research programme expansion
Opportunities this could create
- Clinical operations
- Scientific hiring
- Licensing and BD partnerships
- Market-entry advisers
- Local employment infrastructure
Based on the Biotech & Pharma sector, a Series B round and the priorities the company itself set out. Not a statement of fact.
- 3 September 2026$60M Series B announced
- 3 September 2026Stated priority: market expansion
- 3 September 2026Stated priority: research and development
High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.
Momentum Inferred
AfterRaise Score
- Hiring momentum Open roles and hiring pace
- Market expansion New offices and new countries
- Leadership Executive appointments
- Product activity Launches and releases
Growth timeline
What has happened so far
- 3 September 2026$60M Series BLed by BVF Partners.
Observed The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.
Moves
Published by the company
No company-published Moves yet
AfterRaise has the funding facts for Superluminal Medicines from public sources. What it does not have is what the company is doing next, in the company's own words. That part only they can write.
Work here? Publish the first MoveOpportunities
Work this company has opened
No open Opportunities listed
Jobs, projects, partnerships and advisory needs appear here once the company has claimed its room and published them.
Work here? Open the first oneOpen to
Who may approach Superluminal Medicines
Not yet specified
Superluminal Medicines has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.
Work here? Set your preferencesHelpful contributors
People who have contributed here
Nobody yet
When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.
Work here?
Own your growth story.
This room belongs to Superluminal Medicines. Claim it to tell people where you are going, confirm or correct what AfterRaise noticed, publish Moves, ask the network, control who can contact you, and share your growth story. Everything you publish is reviewed before it appears.
What we do not have yet: your website and the roles and projects you have open. Claiming the room is how you fill those in.
Also moving